Document Detail


Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities.
MedLine Citation:
PMID:  17018693     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Increased Rho kinase (ROCK) activity contributes to smooth muscle contraction and regulates blood pressure homeostasis. We hypothesized that potent and selective ROCK inhibitors with novel structural motifs would help elucidate the functional role of ROCK and further explore the therapeutic potential of ROCK inhibition for hypertension. In this article, we characterized two aminofurazan-based inhibitors, GSK269962A [N-(3-{[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4, 5-c]pyridin-6-yl]oxy}phenyl)-4-{[2-(4-morpholinyl)ethyl]-oxy}benzamide] and SB-7720770-B [4-(7-{[(3S)-3-amino-1-pyrrolidinyl]carbonyl}-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-amine], as members of a novel class of compounds that potently inhibit ROCK enzymatic activity. GSK269962A and SB-772077-B have IC50 values of 1.6 and 5.6 nM toward recombinant human ROCK1, respectively. GSK269962A also exhibited more than 30-fold selectivity against a panel of serine/threonine kinases. In lipopolysaccharide-stimulated monocytes, these inhibitors blocked the generation of inflammatory cytokines, such as interleukin-6 and tumor necrosis factor-alpha. Furthermore, both SB-772077-B and GSK269962A induced vasorelaxation in preconstricted rat aorta with an IC50 of 39 and 35 nM, respectively. Oral administration of either GSK269962A or SB-772077-B produced a profound dose-dependent reduction of systemic blood pressure in spontaneously hypertensive rats. At doses of 1, 3, and 30 mg/kg, both compounds induced a reduction in blood pressure of approximately 10, 20, and 50 mm Hg. In addition, administration of SB-772077-B also dramatically lowered blood pressure in DOCA salt-induced hypertensive rats. SB-772077-B and GSK269962A represent a novel class of ROCK inhibitors that have profound effects in the vasculature and may enable us to further evaluate the potential beneficial effects of ROCK inhibition in animal models of cardiovascular as well as other chronic diseases.
Authors:
Chris Doe; Ross Bentley; David J Behm; Robert Lafferty; Robert Stavenger; David Jung; Mark Bamford; Terry Panchal; Eugene Grygielko; Lois L Wright; Gary K Smith; Zunxuan Chen; Christine Webb; Sanjay Khandekar; Tracey Yi; Robert Kirkpatrick; Edward Dul; Larry Jolivette; Joseph P Marino; Robert Willette; Dennis Lee; Erding Hu
Related Documents :
1741993 - Physiological effects of the humoral renomedullary antihypertensive system.
1986983 - Effect of enalapril treatment on the pressure-natriuresis curve in spontaneously hypert...
10369383 - Function of the isolated perfused kidneys from young or adult rats with post-doca-salt ...
Publication Detail:
Type:  Journal Article     Date:  2006-10-03
Journal Detail:
Title:  The Journal of pharmacology and experimental therapeutics     Volume:  320     ISSN:  0022-3565     ISO Abbreviation:  J. Pharmacol. Exp. Ther.     Publication Date:  2007 Jan 
Date Detail:
Created Date:  2006-12-21     Completed Date:  2007-02-12     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0376362     Medline TA:  J Pharmacol Exp Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  89-98     Citation Subset:  IM    
Affiliation:
Department of Investigational Biology, Centres of Excellence for Cardiovascular Urogenital Drug Discovery, Discovery Research, GlaxoSmithKline Pharmaceuticals Inc., King of Prussia, PA 19406, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Anti-Inflammatory Agents / pharmacology*
Antihypertensive Agents / pharmacology
Cells, Cultured
Cytokines / biosynthesis
Humans
Imidazoles / pharmacology*
Intracellular Signaling Peptides and Proteins / antagonists & inhibitors*
Macrophages / drug effects,  immunology
Male
Oxadiazoles / pharmacology*
Protein Kinase Inhibitors / pharmacology*
Protein-Serine-Threonine Kinases / antagonists & inhibitors*
Rats
Rats, Inbred SHR
Rats, Inbred WKY
Vasodilator Agents / pharmacology*
rho-Associated Kinases
Chemical
Reg. No./Substance:
0/4-(7-((3-amino-1-pyrrolidinyl)carbonyl)-1-ethyl-1H-imidazo(4,5-c)pyridin-2-yl)-1,2,5-oxadiazol-3-amine; 0/Anti-Inflammatory Agents; 0/Antihypertensive Agents; 0/Cytokines; 0/Imidazoles; 0/Intracellular Signaling Peptides and Proteins; 0/N-(3-((2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo(4,5-c)pyridin-6-yl)oxy)phenyl)-4-((2-(4-morpholinyl)ethyl)oxy)benzamide; 0/Oxadiazoles; 0/Protein Kinase Inhibitors; 0/ROCK1 protein, human; 0/Vasodilator Agents; EC 2.7.11.1/Protein-Serine-Threonine Kinases; EC 2.7.11.1/rho-Associated Kinases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Lack of the aryl hydrocarbon receptor leads to impaired activation of AKT/protein kinase B and enhan...
Next Document:  Cannabinoid (CB1) receptor activation inhibits trigeminovascular neurons.